Key result
Higher-dose sitagliptin lowers HbA1c by ~0.4% more than conventional therapy and slows carotid IMT progression.
Why the study?
The dose-dependent effect relationship between DPP-4 inhibitors and atherosclerosis in patients with type 2 diabetes mellitus treated with insulin had not been investigated.
Does a higher dose of sitagliptin reduce the progression of carotid atherosclerosis in patients with T2DM receiving insulin?
Comparison
Higher sitagliptin dose vs lower sitagliptin dose vs conventional treatment
Design
Randomized controlled trial with post hoc analysis
Follow-up
104 weeks
Authors
Loading...
May support dose-dependent carotid IMT slowing with higher sitagliptin in insulin-treated T2DM; leaves open need for prospective confirmation before practice change.
RCT (n=274)
randomized
Does a higher dose of sitagliptin reduce the progression of carotid atherosclerosis in patients with T2DM receiving insulin?
Absolute Event Rate: -0.62% vs -0.2%
p-value: p=0.007
Higher doses of sitagliptin added to insulin therapy may attenuate the progression of carotid atherosclerosis in patients with type 2 diabetes.
Mita et al. (2017) conducted an RCT in Type 2 diabetes mellitus (n=274). Sitagliptin vs. Conventional treatment was evaluated on HbA1c reduction and mean intima media thickness-common carotid artery (IMT-CCA) progression (p=0.007). Higher dose sitagliptin significantly reduced HbA1c (-0.62% vs -0.20%, P=0.007) and inhibited the progression of mean IMT-CCA compared with conventional treatment over 104 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: